Slingshot members are tracking this event:
Phase 3 Topline data of Neurocrine's (NBIX) Elagolix in treating Uterine Fibroids expected Q1 2018
Do you think this event is important to the companies below? How will it affect their stock price?
Both higher and lower doses of elagolix were effective in improving dysmenorrhea and nonmenstrual pelvic pain during a 6-month period in women with endometriosis-associated pain. The two doses of elagolix were associated with hypoestrogenic adverse effects.
Slingshot Insights Explained
Feb 21, 2018
Don’t see a project related to the catalyst you care about?
Related Keywords Elagolix, Phase 3, Uterine Fibroids, Alkaline Hematin